ArticleMolecular medicine (Cambridge, Mass.)2026
Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundA subset of hormone-sensitive prostate cancer (HSPC) exhibits low prostate-specific membrane antigen (PSMA) uptake on PET imaging, which may limit the performance of PSMA-based detection and PSMA-directed therapeutic strategies. However, the clinical features and molecular basis of HSPC with low PSMA expression remain incompletely defined.
methodsWe first analyzed a retrospective dual-tracer PET cohort to estimate the frequency and clinical characteristics of tumors with low PSMA uptake at initial diagnosis. We then collected radical prostatectomy specimens for proteomics profiling, classifying tumors as low-PSMA (N = 16) or high-PSMA (N = 19) based on concordant [
resultsLow-PSMA HSPC was identified in 7.23% (122/1,688) of patients in the retrospective dual-tracer PET cohort, indicating that reduced PSMA uptake is already observable at initial diagnosis. Although these tumors showed reduced PSMA expression, they were not uniformly low-risk, with 42.62% of cases exhibiting Gleason score ≥ 8. In the proteomic cohort, low-PSMA tumors showed concordant reductions in PSMA uptake and protein expression, supporting imaging-pathology alignment. Proteomic analysis revealed a distinct molecular state characterized by enrichment of tissue remodeling, repair, epithelial organization, and microenvironment-related programs, together with attenuation of androgen-response, E2F, and MYC-associated proliferative signaling. Cell-surface membrane surface target prioritization identified ALCAM and TACSTD2 as candidates, among which ALCAM was consistently upregulated in low-PSMA tumors at both mRNA and protein levels.
conclusionsHSPC with low PSMA expression represents a distinct clinical and molecular state rather than a simple low-risk subgroup. Its proteomic features suggest altered epithelial differentiation, tissue remodeling, and reduced canonical prostate cancer signaling. ALCAM may serve as a complementary membrane biomarker for improving the molecular recognition of low-PSMA HSPC and supporting future alternative imaging or targeting strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.